Immuneering Corp Stock Investor Sentiment

IMRX Stock  USD 2.09  0.04  1.88%   
Slightly above 56% of Immuneering Corp's investor base is looking to short. The analysis of the overall investor sentiment regarding Immuneering Corp suggests that many traders are alarmed. Immuneering Corp's investing sentiment can be driven by a variety of factors including economic data, Immuneering Corp's earnings reports, geopolitical events, and overall market trends.
  

Immuneering Corp Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Immuneering Corp can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
2 days ago at finance.yahoo.com         
Immuneering to Present at the Piper Sandler 36 Annual Healthcare Conference
Yahoo News
2 days ago at globenewswire.com         
Immuneering to Present at the Piper Sandler 36 Annual Healthcare Conference
Macroaxis News: globenewswire.com
2 days ago at gurufocus.com         
Immuneering to Present at the Piper Sandler 36 Annual Healthcare Conference
Gurufocus Stories at Macroaxis
few days ago at investing.com         
Immuneering shares retain Outperform rating amid Phase 2a progress for IMM-1-104
Investing News at Macroaxis
over a week ago at news.google.com         
Immuneering Co. Given Consensus Recommendation of Moderate Buy by Brokerages - MarketBeat
Google News at Macroaxis
over a week ago at news.google.com         
Immuneering Corp. Reports Q3 Loss, Highlights Progress - TipRanks
Google News at Macroaxis
over two weeks ago at seekingalpha.com         
Immuneering GAAP EPS of -0.49
seekingalpha News
over two weeks ago at globenewswire.com         
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
Macroaxis News: globenewswire.com
over two weeks ago at www.macroaxis.com         
Disposition of 60500 shares by Leah Neufeld of Immuneering Corp at 6.09 subject to Rule 16b-3
Macroaxis News
over three weeks ago at www.macroaxis.com         
Acquisition by Leah Neufeld of 60500 shares of Immuneering Corp at 6.09 subject to Rule 16b-3
Macroaxis News
over a month ago at simplywall.st         
Immuneering Slides As Insider Purchases Lose Another US82k
Simply Wall St News at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Feinberg Peter of 25000 shares of Immuneering Corp at 2.5485 subject to Rule 16b-3
Macroaxis News
over a month ago at finance.yahoo.com         
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Canc...
Yahoo News
over a month ago at finance.yahoo.com         
Heres Why Were A Bit Worried About Immuneerings Cash Burn Situation
Yahoo News
over a month ago at thelincolnianonline.com         
Analysts Set Immuneering Co. Target Price at 12.60
news
Far too much social signal, news, headlines, and media speculation about Immuneering Corp that are available to investors today. That information is available publicly through Immuneering media outlets and privately through word of mouth or via Immuneering internal channels. However, regardless of the origin, that massive amount of Immuneering data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Immuneering Corp news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immuneering Corp relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immuneering Corp's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immuneering Corp alpha.

Immuneering Corp Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of tradable shares by Morales Mallory of Immuneering Corp subject to Rule 16b-3
09/11/2024
2
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Panc...
09/12/2024
3
Acquisition by Morales Mallory of 4458 shares of Immuneering Corp at 1.6235 subject to Rule 16b-3
09/13/2024
4
Immuneering Co. to Post FY2024 Earnings of Per Share, Chardan Capital Forecasts
09/18/2024
5
Acquisition by Bookman Michael of 101116 shares of Immuneering Corp at 3.01 subject to Rule 16b-3
09/20/2024
6
Heres Why Were A Bit Worried About Immuneerings Cash Burn Situation
10/14/2024
7
Acquisition by Feinberg Peter of 25000 shares of Immuneering Corp at 2.5485 subject to Rule 16b-3
10/25/2024
8
Acquisition by Leah Neufeld of 60500 shares of Immuneering Corp at 6.09 subject to Rule 16b-3
10/31/2024
9
Disposition of 60500 shares by Leah Neufeld of Immuneering Corp at 6.09 subject to Rule 16b-3
11/08/2024
10
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
11/13/2024
11
Immuneering Co. Given Consensus Recommendation of Moderate Buy by Brokerages - MarketBeat
11/20/2024
12
Immuneering to Present at the Piper Sandler 36 Annual Healthcare Conference
11/27/2024

Additional Tools for Immuneering Stock Analysis

When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.